Bain and Cinven seek full control over Stada
This article was originally published in OTC Bulletin & The Rose Sheet
Stada Arzneimittel’s controlling shareholders, Bain Capital and Cinven, have made an improved offer to minority shareholders as they seek to take full control of the German generics and OTC specialist and delist the company.
You may also be interested in...
After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.
The HMA-EMA Big Data Task Force has offered recommendations to use data for the benefit of public health.